תוצאות חיפוש - Mark S. Berger

  • Showing 1 - 9 results of 9
Refine Results
  1. 1
    A phase I/II study of the pan Bcl-2 inhibitor obatoclax mesylate plus bortezomib for relapsed or refractory mantle cell lymphoma

    A phase I/II study of the pan Bcl-2 inhibitor obatoclax mesylate plus bortezomib for relapsed or refractory mantle cell lymphoma מאת André Goy, Francisco J. Hernandez-Ilzaliturri, Brad S. Kahl, Peggy Ford, Ewelina Protomastro, Mark S. Berger

    יצא לאור 2014
    קבל טקסט מלא
    Artigo
    הוספה למועדפים
    שמור ב:
  2. 2
    Daratumumab- <sup>225</sup> Actinium conjugate demonstrates greatly enhanced antitumor activity against experimental multiple myeloma tumors

    Daratumumab- <sup>225</sup> Actinium conjugate demonstrates greatly enhanced antitumor activity against experimental multiple myeloma tumors מאת Wojciech Dawicki, Kevin J. Allen, Rubin Jiao, Mackenzie E. Malo, Muath Helal, Mark S. Berger, Dale L. Ludwig, Ekaterina Dadachova

    יצא לאור 2019
    קבל טקסט מלא קבל טקסט מלא
    Artigo
    הוספה למועדפים
    שמור ב:
  3. 3
    Phase I Dose Finding Studies of Obatoclax (GX15-070), a Small Molecule Pan-BCL-2 Family Antagonist, in Patients with Advanced Solid Tumors or Lymphoma

    Phase I Dose Finding Studies of Obatoclax (GX15-070), a Small Molecule Pan-BCL-2 Family Antagonist, in Patients with Advanced Solid Tumors or Lymphoma מאת Jimmy J. Hwang, John Kuruvilla, David S. Mendelson, Michael J. Pishvaian, John F. Deeken, Lillian L. Siu, Mark S. Berger, Jean Viallet, John L. Marshall

    יצא לאור 2010
    קבל טקסט מלא קבל טקסט מלא
    Artigo
    הוספה למועדפים
    שמור ב:
  4. 4
    Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin

    Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin מאת Michael Linenberger, Tom C. Hong, David Flowers, Eric L. Sievers, Ted Gooley, John M. Bennett, Mark S. Berger, Lance Leopold, Frederick R. Appelbaum, Irwin D. Bernstein

    יצא לאור 2001
    קבל טקסט מלא
    Artigo
    הוספה למועדפים
    שמור ב:
  5. 5
    Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer

    Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer מאת Henry Gómez, Dinesh Chandra Doval, Miguel A. Chavez, Peter Ang, Zeba Aziz, Shona Nag, Christina Ng, Sandra Franco, Louis W.C. Chow, Michael Arbushites, Michelle Casey, Mark S. Berger, Steven H. Stein, George W. Sledge

    יצא לאור 2008
    קבל טקסט מלא קבל טקסט מלא
    Artigo
    הוספה למועדפים
    שמור ב:
  6. 6
    Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer

    Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer מאת Charles E. Geyer, John Forster, Deborah Lindquist, Stephen Chan, C. Gilles Romieu, Tadeusz Pieńkowski, Agnieszka Jagiełło-Gruszfeld, John Crown, Arlene Chan, Bella Kaufman, Dimosthenis Skarlos, Mario Campone, Neville Davidson, Mark S. Berger, Cristina Oliva, Stephen D. Rubin, Steven Stein, David Cameron

    יצא לאור 2006
    קבל טקסט מלא קבל טקסט מלא
    Artigo
    הוספה למועדפים
    שמור ב:
  7. 7
    A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in Patients with Advanced Hematologic Malignancies

    A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in Patients with Advanced Hematologic Malignancies מאת Aaron D. Schimmer, Susan O’Brien, Hagop M. Kantarjian, Joseph Brandwein, Bruce D. Cheson, Mark D. Minden, Karen Yee, Farhad Ravandi, Francis J. Giles, Andre C. Schuh, Vikas Gupta, Michael Andreeff, Charles Koller, Hong Chang, Suzanne Kamel‐Reid, Mark S. Berger, Jean Viallet, Gautam Borthakur

    יצא לאור 2008
    קבל טקסט מלא קבל טקסט מלא
    Artigo
    הוספה למועדפים
    שמור ב:
  8. 8
    Single-cell transcriptional diversity is a hallmark of developmental potential

    Single-cell transcriptional diversity is a hallmark of developmental potential מאת Gunsagar S. Gulati, Shaheen S. Sikandar, Daniel J. Wesche, Anoop Manjunath, Anjan Bharadwaj, Mark J. Berger, Francisco Ilagan, Angera H. Kuo, Robert W. Hsieh, Shang Cai, Maider Zabala, Ferenc A. Scheeren, Neethan A. Lobo, Dalong Qian, Feiqiao Brian Yu, Frederick M. Dirbas, Michael F. Clarke, Aaron M. Newman

    יצא לאור 2020
    קבל טקסט מלא
    Artigo
    הוספה למועדפים
    שמור ב:
  9. 9
    Cutting Edge: Selective Oral ROCK2 Inhibitor Reduces Clinical Scores in Patients with Psoriasis Vulgaris and Normalizes Skin Pathology via Concurrent Regulation of IL-17 and IL-10

    Cutting Edge: Selective Oral ROCK2 Inhibitor Reduces Clinical Scores in Patients with Psoriasis Vulgaris and Normalizes Skin Pathology via Concurrent Regulation of IL-17 and IL-10 מאת Alexandra Zanin‐Zhorov, Jonathan M. Weiss, Alissa Trzeciak, Wei Chen, Jingya Zhang, Melanie S. Nyuydzefe, Carmen Arencibia, Seetharam Polimera, Olivier Schueller, Judilyn Fuentes‐Duculan, Kathleen M. Bonifacio, Norma Kunjravia, Inna Cueto, Jennifer Soung, Roy Fleischmann, Alan Kivitz, Mark Lebwohl, Margarita Núñez, Johnnie Woodson, Shondra Smith, Robert F. West, Mark S. Berger, James G. Krueger, John L. Ryan, Samuel D. Waksal

    יצא לאור 2017
    קבל טקסט מלא
    Artigo
    הוספה למועדפים
    שמור ב:

כלי חיפוש: